About this Journal Submit a Manuscript Table of Contents
ISRN Immunology
Volume 2012 (2012), Article ID 324235, 10 pages
http://dx.doi.org/10.5402/2012/324235
Clinical Study

The Florida Melanoma Trial I: A Prospective Multicenter Phase I/II Trial of Postoperative Hypofractionated Adjuvant Radiotherapy with Concurrent Interferon-Alfa-2b in the Treatment of Advanced Stage III Melanoma with Long-Term Toxicity Follow-Up

1Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
221st Century Oncology Translational Research Consortium, Scottsdale, AZ 85251, USA
3Department of Surgery, University of South Florida, Tampa, FL 33612, USA
4Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
5Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33146, USA
6Department of Biostatistics, Moffitt Cancer Center, Tampa, FL 33612, USA
7Health Outcomes & Behavior Program, Moffitt Cancer Center, Tampa, FL 33612, USA

Received 8 September 2011; Accepted 16 October 2011

Academic Editors: A. Bensussan and D. Saverino

Copyright © 2012 Steven E. Finkelstein et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Steven E. Finkelstein, Andy Trotti, Nikhil Rao, et al., “The Florida Melanoma Trial I: A Prospective Multicenter Phase I/II Trial of Postoperative Hypofractionated Adjuvant Radiotherapy with Concurrent Interferon-Alfa-2b in the Treatment of Advanced Stage III Melanoma with Long-Term Toxicity Follow-Up,” ISRN Immunology, vol. 2012, Article ID 324235, 10 pages, 2012. doi:10.5402/2012/324235